Calliditas Therapeutics: Interim Report Q1, 2020

Calliditas Therapeutics: Interim Report Q1, 2020

PR Newswire

STOCKHOLM, May 14, 2020

- NefIgArd proceeding according to plan

STOCKHOLM, May 14, 2020 /PRNewswire/ -- "In the end of the first quarter of 2020 much of the activity at the company was focused on assessing and mitigating any potential impact Covid-19 might have on NefIgArd and I am happy to report that, due to the fact that the Part A of the study was fully recruited in December 2019, Nefecon is an oral formulation which patients are able to take at home and that the study doesn't require significant interactions with the healthcare system, the impact to date has been limited and our communicated timeline remain intact"

Renée Aguiar-Lucander, CEO

Summary of Q1 2020

January 1 - March 31, 2020        

Significant events during Q1 2020, in summary          

Significant events after the end of reporting period, in summary           

Investor presentation May 14, 15:30 CET

Audio cast with teleconference, Q1 2020, May 14, 2020, 15:30 (Europe/Stockholm)


Teleconference: Dial-in number SE: +46850558350; UK: +443333009034; US: 1833526834795

Financial calendar

Interim report for the period January 1 - June 30, 2020  August 13, 2020

Interim report for the period January 1 - September 30, 2020  November 12, 2020

Year-end report for the period January 1 - December 31, 2020  February 18, 2021

The information was submitted for publication, through the agency of the contact persons set out above, at 07:00 CET on May 14, 2020.

About Calliditas Therapeutics

Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the Company can partially or completely participate in the commercialization efforts. The Company is focused on the development and commercialization of the product candidate Nefecon, a unique two-step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas Therapeutics is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the US. The company is listed on Nasdaq Stockholm (ticker: CALTX). Visit for further information.

For further information, please contact:
Renée Aguiar-Lucander, CEO at Calliditas
Telephone: +46-722-52-10-06

Mikael Widell, Head of Communications at Calliditas
Telephone: +46-703-11-99-60

This information was brought to you by Cision,c3111672

The following files are available for download:


Press release Q1 2020 ENG


Voltar noticias em Inglês